Wheeler Bio
Wheeler Bio is a biomanufacturing company dedicated to accelerating the translation of therapeutic innovation into clinical impact. With a focus on biologics and antibody therapeutics, Wheeler offers a comprehensive discovery-to-IND program, leveraging innovative platforms like Portable CMC® to streamline drug development, reduce costs, and improve process reliability. The company is committed to digital transformation, industry collaboration, and building a future-ready biomanufacturing ecosystem in Oklahoma City, supporting emerging biopharma companies and advancing patient access to life-changing therapies.
Industries
Nr. of Employees
medium (51-250)
Wheeler Bio
Oklahoma City, Oklahoma, United States, North America
Products
Lead Selection
Program type combining work packages for transfection to top pool selection in as few as 3 months.
Fc-Fusion Protein Development and Manufacturing
Development of Fc-fusion therapeutics through integrated, phase-appropriate development and manufacturing solutions designed to advance complex biologics efficiently toward the clinic and beyond.
ModularCMC
A platform framework providing integrated IND/CTA-enabling services for monoclonal antibody development, covering cell line development, process development, analytical development, formulation, and cGMP drug substance and drug product manufacturing.
cGMP Drug Substance Manufacturing
Execution of fed-batch production campaigns in single-use bioreactor systems to deliver formulated bulk drug substance.
Lead to Clinic and Beyond
Comprehensive program type from transfection to drug product release in as few as 10 months.
Integrated GMP
Integrated cGMP manufacturing of drug substance and drug product for antibody therapeutics from early development through clinical supply.
Lead Selection
Program type combining work packages for transfection to top pool selection in as few as 3 months.
Fc-Fusion Protein Development and Manufacturing
Development of Fc-fusion therapeutics through integrated, phase-appropriate development and manufacturing solutions designed to advance complex biologics efficiently toward the clinic and beyond.
ModularCMC
A platform framework providing integrated IND/CTA-enabling services for monoclonal antibody development, covering cell line development, process development, analytical development, formulation, and cGMP drug substance and drug product manufacturing.
cGMP Drug Substance Manufacturing
Execution of fed-batch production campaigns in single-use bioreactor systems to deliver formulated bulk drug substance.
Lead to Clinic and Beyond
Comprehensive program type from transfection to drug product release in as few as 10 months.
Integrated GMP
Integrated cGMP manufacturing of drug substance and drug product for antibody therapeutics from early development through clinical supply.
Services
Rapid transient CHO- and HEK-based protein expression for construct screening and generation of mg–g scale material for discovery and preclinical studies.
Mammalian CHO cell line development and genome engineering services including single-cell isolation, imaging, high-throughput clone screening, and stable production cell line generation for scalable manufacturing.
Upstream and downstream process development using DoE and high-throughput tools to create scalable, robust processes for tox and clinical supply.
Method development, qualification, stability testing, and analytical characterization to support release testing and regulatory submissions.
Formulation screening and optimization for bulk liquid formulations using DoE and machine-learning assisted approaches to meet stability requirements.
Generation and supply of preclinical/toxicity study material from development platforms or transferred client processes to support GLP studies.
Rapid transient CHO- and HEK-based protein expression for construct screening and generation of mg–g scale material for discovery and preclinical studies.
Mammalian CHO cell line development and genome engineering services including single-cell isolation, imaging, high-throughput clone screening, and stable production cell line generation for scalable manufacturing.
Upstream and downstream process development using DoE and high-throughput tools to create scalable, robust processes for tox and clinical supply.
Method development, qualification, stability testing, and analytical characterization to support release testing and regulatory submissions.
Formulation screening and optimization for bulk liquid formulations using DoE and machine-learning assisted approaches to meet stability requirements.
Generation and supply of preclinical/toxicity study material from development platforms or transferred client processes to support GLP studies.
Expertise Areas
- CMC process development for biologics
- Mammalian cell line development and genome engineering
- Protein expression and purification for discovery and preclinical supply
- Analytical method development and qualification
Key Technologies
- CHO and HEK mammalian expression systems
- Transposase-mediated stable genome integration
- Single-cell isolation and imaging
- High-throughput clone screening and miniaturized bioreactors
News & Updates
Wheeler Bio has announced an oversubscribed Series A-1 funding round to support its growth and expansion plans.
Patrick Lucy has been appointed as the new CEO of Wheeler Bio, bringing industry experience to lead the company's growth.
Wheeler Bio has licensed ATUM’s proprietary miFuc™ technology to enhance its Portable CMC platform.
Wheeler Bio’s facility has been selected as a finalist for the ISPE Facility of the Year Awards.
Wheeler Bio and Charles River Laboratories have announced a partnership to offer Portable CMC services.
An article discussing innovative approaches to biomanufacturing and CDMO services.
Wheeler Bio has announced an oversubscribed Series A-1 funding round to support its growth and expansion plans.
Patrick Lucy has been appointed as the new CEO of Wheeler Bio, bringing industry experience to lead the company's growth.
Wheeler Bio has licensed ATUM’s proprietary miFuc™ technology to enhance its Portable CMC platform.
Wheeler Bio’s facility has been selected as a finalist for the ISPE Facility of the Year Awards.
Wheeler Bio and Charles River Laboratories have announced a partnership to offer Portable CMC services.
An article discussing innovative approaches to biomanufacturing and CDMO services.